###begin article-title 0
A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Interleukin 4 (IL-4) is a key regulator of the immune system and an important factor in the development of allergic hypersensitivity. Together with interleukin 13 (IL-13), IL-4 plays an important role in exacerbating allergic and asthmatic symptoms. For signal transduction, both cytokines can utilise the same receptor, consisting of the IL-4Ralpha and the IL-13Ralpha1 chain, offering an explanation for their overlapping biological functions. Since both cytokine ligands share only moderate similarity on the amino acid sequence level, molecular recognition of the ligands by both receptor subunits is of great interest. IL-4 and IL-13 are interesting targets for allergy and asthma therapies. Knowledge of the binding mechanism will be important for the generation of either IL-4 or IL-13 specific drugs.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 150 159 150 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 452 455 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 881 884 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
We present a structure/function analysis of the IL-4 ligand-receptor interaction. Structural determination of a number of IL-4 variants together with in vitro binding studies show that IL-4 and its high-affinity receptor subunit IL-4Ralpha interact via a modular protein-protein interface consisting of three independently-acting interaction clusters. For high-affinity binding of wild-type IL-4 to its receptor IL-4Ralpha, only two of these clusters (i.e. cluster 1 centered around Glu9 and cluster 2 around Arg88) contribute significantly to the free binding energy. Mutating residues Thr13 or Phe82 located in cluster 3 to aspartate results in super-agonistic IL-4 variants. All three clusters are fully engaged in these variants, generating a three-fold higher binding affinity for IL-4Ralpha. Mutagenesis studies reveal that IL-13 utilizes the same main binding determinants, i.e. Glu11 (cluster 1) and Arg64 (cluster 2), suggesting that IL-13 also uses this modular protein interface architecture.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 246 249 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
The modular architecture of the IL-4-IL-4Ralpha interface suggests a possible mechanism by which proteins might be able to generate binding affinity and specificity independently. So far, affinity and specificity are often considered to co-vary, i.e. high specificity requires high affinity and vice versa. Although the binding affinities of IL-4 and IL-13 to IL-4Ralpha differ by a factor of more than 1000, the specificity remains high because the receptor subunit IL-4Ralpha binds exclusively to IL-4 and IL-13. An interface formed by several interaction clusters/binding hot-spots allows for a broad range of affinities by selecting how many of these interaction clusters will contribute to the overall binding free energy. Understanding how proteins generate affinity and specificity is essential as more and more growth factor receptor families show promiscuous binding to their respective ligands. This limited specificity is, however, not accompanied by low binding affinities.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Interleukin 4 (IL-4) is a pleiotropic cytokine that plays a major regulatory role in the immune system [1]. IL-4 induces the differentiation of T-helper cells to a type 2 (TH2) cytokine-producing phenotype [2] and the class switching to IgE and IgG4 [3,4]. Furthermore, it stimulates the expression of adhesion molecules such as VCAM-1 [5] and chemokines such as eotaxin-1, -2 and -3 [6-8]. Activated TH2 cells play a triggering role in the activation and/or recruitment of IgE antibody-producing B cells, mast cells [9] and eosinophils [10], which are all involved in allergic inflammation [11]. Therefore, IL-4 plays a key role in the development and progression of allergic hypersensitivity.
###end p 9
###begin p 10
###xml 186 188 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 328 329 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 332 334 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 335 337 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 366 368 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 369 371 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 451 453 435 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 531 533 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 534 536 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 609 611 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Signal transduction of IL-4 is mediated by a sequential binding process, initiated first by binding of IL-4 to its high-affinity single membrane spanning receptor chain IL-4Ralpha (Fig. 1a). This intermediate ligand receptor complex then recruits one of two possible low-affinity receptor subunits, the common gamma chain (gammac) [12,13] or the IL-13Ralpha1 chain [14,15], into the functional hetero-trimeric complex to initiate signalling. The gammac receptor subunit is shared among the cytokines IL-2, -4, -7, -9, -15 and -21 [12,13], whereas the IL-13Ralpha1 subunit is exclusively used by IL-4 and -13 [16].
###end p 10
###begin p 11
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequential binding mechanism in the IL-4/-13 receptor activation</bold>
###xml 321 322 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 322 324 314 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 341 343 328 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 349 350 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 350 352 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 571 572 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 572 574 550 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 700 701 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 701 702 670 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D</sub>
###xml 1294 1296 1243 1245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
Sequential binding mechanism in the IL-4/-13 receptor activation. (a) The binding of IL-4 to its cellular receptor follows a two-step sequential binding mechanism. First, IL-4 is recruited to the membrane by its high-affinity subunit IL-4Ralpha; second, either one of the two low affinity subunits IL-13Ralpha1 (apparent KD ~ 1 muM) or gammac (app. KD ~ 1.5 - 2 muM) is recruited into the complex. (b) For IL-13 the order of the binding events is reversed. IL-13 binds first to the IL-13Ralpha1 subunit; the affinity of IL-13 to IL-4Ralpha is below detection limit (app. KD > 100 muM). In the second step the IL-13:IL-13Ralpha1 complex recruits the IL-4Ralpha subunit into the complex. Values marked KD* indicate that these interactions are measured by binding of the soluble ectodomain to the surface immobilized binary complex of ligand and high-affinity receptor subunits. These apparent binding constants do not reflect the real affinity for a two-dimensional interaction in the membrane. (c, d) The location of the binding sites for the receptor subunits IL-4Ralpha and IL-13Ralpha1 are conserved between the two cytokines IL-4 (c) and IL-13 (d). Site 1 is used for the interaction with the IL-4Ralpha subunit, site 2 is used for the interaction with IL-13Ralpha1 (and for binding to gammac in the case of IL-4).
###end p 11
###begin p 12
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 224 226 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 229 231 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 685 687 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 690 692 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 841 842 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 842 844 818 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 869 871 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 952 954 920 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 955 957 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1023 1025 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 1101 1110 1069 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1118 1119 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1119 1121 1087 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1136 1138 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1233 1234 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1234 1236 1198 1200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1355 1356 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1356 1358 1312 1314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1451 1453 1407 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1456 1458 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
IL-13 shares only 25% identity with IL-4 on the amino acid sequence level [17]. Despite this moderate homology, IL-13 and IL-4 utilize an identical cellular receptor built from the subunits IL-4Ralpha and IL-13Ralpha1 (Fig. 1b) [16]. However, the order of the binding sequence and binding affinities to the individual receptor subunits differ markedly between the two cytokines. In contrast to IL-4, IL-13 binds first to the IL-13Ralpha1 subunit with high affinity and subsequently recruits the IL-4Ralpha chain as the low-affinity receptor subunit into the complex. High-affinity binding of IL-4 to its cellular receptor is mediated almost exclusively by the IL4-Ralpha subunit (Fig. 1a) [18]. The binding of IL-4 to the extracellular domain of IL-4Ralpha determined by surface plasmon resonance spectroscopy yields a dissociation constant KD of approx. 0.1 - 0.2 nM [19]. In the case of IL-4, the low-affinity receptor subunits IL-13Ralpha1 and gammac [20] seem to contribute little to the overall binding affinity (Fig. 1a). For IL-13, only binding to its high-affinity subunit has been determined in vitro so far (KD ~ 25 - 50 nM) [21], and this is confirmed by binding experiments using CHO cells transfected with IL-13Ralpha1 (KD ~ 4 - 5 nM). Binding to the receptor formed from IL-13Ralpha1 and IL-4Ralpha leads to a dramatic increase in affinity (KD ~ 30 - 40 pM), suggesting a strong cooperativity for binding to both receptor subunits (Fig. 1b) [15].
###end p 12
###begin p 13
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 342 347 342 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c, d</xref>
###xml 526 528 518 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 547 549 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 550 552 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 556 558 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 559 561 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 774 776 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 999 1001 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1186 1188 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1189 1191 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
The structures of both cytokine ligands IL-4 and IL-13 have been determined by x-ray crystallography or by NMR [22-27]. Both IL-4 and IL-13 belong to the short-chain 4-helix bundle cytokines. The four anti-parallel helices A, C, B and D are connected by two long end-to-end loops AB and CD and one short loop connecting helices B and C (Fig. 1c, d). Structure-function analyses of IL-4 have revealed insights into the architecture and composition of the binding epitopes involved in the binding to the IL-4Ralpha and the gammac receptor subunits [18-20], [28-32]. Structure determination of the ligand-receptor complex of IL-4 bound to its high-affinity receptor subunit IL-4Ralpha has shown that the protein-protein interface represents a new type of modular architecture [33]. Instead of a continuous binding epitope, three so-called interaction clusters could be identified, which contribute affinity independently and might therefore allow for a scalable affinity to different cytokine ligands [34]. Interestingly, the location of the binding sites for the receptor subunits IL-4Ralpha and IL-13Ralpha1 are conserved in both ligands IL-4 and IL-13, as shown by mutagenesis studies [35-37] and structural analyses, suggesting that similar residues might be involved in the recognition and binding of these receptor subunits. In this paper we explore the possibility that this new architecture is the basis of the high specificity of the IL-4Ralpha subunit for the two cytokines IL-4 and IL-13 and its simultaneous variable binding affinity to both ligand proteins. The results contribute significantly to the understanding of how proteins might generate binding affinity and specificity independently, allowing promiscuous protein-protein interactions.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Two mutations in helix C convert IL-4 into a super-agonist
###end title 15
###begin p 16
###xml 117 119 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 327 330 315 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 636 637 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 637 639 625 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 696 697 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 812 813 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 899 900 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 900 903 884 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 1016 1019 992 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 1044 1046 1020 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 1047 1049 1023 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 1119 1121 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 1129 1130 1105 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1156 1157 1132 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1157 1159 1133 1135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
###xml 1211 1212 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1568 1572 1536 1540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
By mutational analysis, two IL-4 variants were found with higher binding affinity to IL-4Ralpha than wild-type IL-4 [30]. The binding characteristics were analyzed by biosensor-based experiments. An IL-4Ralpha variant (extracellular domain comprising residues 1 to 210), which harbours the mutations C182A and Q207C (IL-4RalphaECD), was used for BIAcore studies allowing the receptor protein to be immobilized in an oriented fashion. The receptor protein was biotinylated via the free thiol group and immobilized on a streptavidin-coated BIAcore CM5 biosensor chip. Analysis of the variants T13D and F82D yielded dissociation constants KD of 0.02 - 0.04 nM and 0.03 - 0.04 nM respectively (Table 1). These values are 2- to 3-fold lower than those for the interaction between wild-type IL-4 and IL-4Ralpha (Table 1). The increase in affinity is mainly attributable to the reduced dissociation rates (koff) of T13D and F82D. Wild-type IL-4 dissociates from the immobilized extracellular domain of IL4Ralpha (IL-4RalphaECD) with a rate of 1.3 x 10-3s-1, which is approximately 2-3 times faster than for T13D or F82D (Fig. 2a; Table 1). The association rates (kon) seem not to be affected by these mutations (Table 1). Therefore, the introduction of an acidic residue does not alter the electrostatic steering effect observed for the IL-4-IL-4Ralpha interaction. Since it is mainly the dissociation process that is altered in the T13D and F82D variants, it can be concluded that an acidic residue at either position 13 or 82 leads to a stabilization of the IL-4-IL4-RalphaECD complex, resulting in IL-4 super-agonists. This indicates that additional non-covalent interactions between the ligand and the receptor ectodomain must be formed.
###end p 16
###begin p 17
BIAcore analysis of IL-4, IL-13 and variants
###end p 17
###begin p 18
###xml 77 81 73 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 261 265 253 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
Association and dissociation rates of IL-4 variants to immobilized IL4-RalphaECD were measured on a BIA2000 system. The rate constants represent mean values of 18 independent measurements with 6 different analyte concentrations. Binding affinities of IL-4RalphaECD to the complex of IL-13/IL-13variant bound to IL-13Ralpha1 were measured via the COINJECT command. Dissociation constants were obtained from equilibrium binding analysis, therefore no rate constants are given. Binding of the IL-13 variants to IL-13Ralpha1 was unaltered compared to wild-type IL-13.
###end p 18
###begin p 19
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BIAcore analysis of super-agonistic IL-4 variants</bold>
###xml 226 229 222 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 377 381 369 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 440 441 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 441 444 433 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 538 542 526 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
BIAcore analysis of super-agonistic IL-4 variants. BIAcore sensorgrams of ligand receptor interactions. Solutions of the indicated IL-4 variants (concentration 10 nM) were perfused over a sensor chip with immobilized IL4RalphaECD. (a) Compared to wild-type IL-4 (green) the super-agonistic variants IL4-T13D (red) and IL4-F82D (cyan) show higher binding-affinities to IL4RalphaECD owing to an approximately 3 times slower dissociation rate koff. (b) The double variant IL4-T13D-F82D (purple) shows no altered binding-affinity to IL4RalphaECD in comparison to wild-type IL-4 (green).
###end p 19
###begin p 20
###xml 214 215 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 215 217 211 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 302 303 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 303 305 299 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 496 498 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 506 507 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 653 655 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1178 1179 1158 1159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 1303 1304 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1304 1306 1280 1282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1323 1324 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1324 1326 1299 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1343 1344 1317 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1344 1346 1318 1320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1442 1444 1411 1413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1456 1457 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1457 1460 1426 1429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D &gt;</sub>
###xml 1685 1686 1649 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1686 1688 1650 1652 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1717 1718 1676 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1718 1720 1677 1679 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1747 1748 1701 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1748 1750 1702 1704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1909 1911 1854 1856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1930 1931 1871 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1931 1933 1872 1874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1962 1963 1898 1899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1963 1965 1899 1901 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1992 1993 1923 1924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1993 1995 1924 1926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 2230 2232 2148 2150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 2238 2243 2156 2161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c, d</xref>
To determine whether the stabilizing effects of the two single mutations T13D and F82D might act in a cooperative manner, we generated the IL-4 double variant T13D-F82D, which we expected to bind IL-4Ralpha with a KD in the sub-picomolar range. However, interaction analysis revealed that the apparent KD of the complex between IL-4Ralpha and this IL-4 variant is higher than that observed for the individual single mutation variants T13D and F82D and is similar to that for wild-type IL-4 (Fig. 2b; Table 1). In addition, the kinetic rate constants, especially the dissociation rate, clearly reflect the binding characteristics of wild-type IL-4 (Fig. 2b). The two amino acid exchanges therefore seem not to act cooperatively; the additional thermodynamic stabilization of T13D and F82D leads to competition, possibly because both variants have identical binding mechanisms. To test whether binding specificity is altered by these mutations, binding to other cytokine receptor subunits was compared with that of wild-type IL-4. Binding to the low-affinity subunits was determined by measuring the affinities of IL-4, T13D and F82D bound to IL-4Ralpha for IL-13Ralpha1 and gammac. Direct binding of IL-4 and the super-agonistic variants to the low-affinity subunit IL-13Ralpha1 was also measured (IL-4: KD = 2.5 muM; T13D: KD = 2.5 muM; F82D: KD = 2.3 muM). The affinity of direct interaction between IL-4 (and T13D as well as F82D) and gammac is too low (KD > 100 muM) to be detected by BIAcore technology. No differences between wild-type IL-4 and the super-agonist variants could be observed; the affinity for IL-13Ralpha1 is similar for all three binary ligand receptor complexes (KD = 1.2 muM IL-4wt:IL-4Ralpha; KD = 1.7 muM T13D:IL-4Ralpha; KD = 1.2 muM F82D:IL-4Ralpha). Similar observations were made for the interaction of IL-4 wild-type and super-agonist proteins with the low-affinity subunit gammac (IL-4:IL-4Ralpha : KD = 1.7 muM; T13D:IL-4Ralpha : KD = 2 muM; F82D:IL-4Ralpha : KD = 1.2 muM). This result indicates that the mutations at positions 13 and 82 in the IL-4Ralpha binding site (site 1) of IL-4 do not alter interactions at the binding site for the two low-affinity receptor subunits IL-13Ralpha1 and gammac (Fig. 1c, d). In addition, the cytokine receptor IL-21R, which shares the highest amino acid sequence similarity with IL-4Ralpha in the extracellular part, was used as a control for specificity. Neither wild-type IL-4 nor the super-agonistic variants T13D and F82D showed any binding to this receptor subunit.
###end p 20
###begin title 21
Structural analysis of super-agonist variants
###end title 21
###begin p 22
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1263 1265 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1299 1303 1299 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b-d</xref>
To elucidate the molecular mechanism by which the two mutations might lead to additional stabilizing interactions, we determined the high-resolution structures of the IL-4 variants T13D and F82D as well as the double variant T13D-F82D. Improvements in the purification procedure, especially the use of fractional ammonium sulfate precipitation steps, enabled us to obtain highly homogenous and pure IL-4 protein, giving a single protein band on silver-stained SDS polyacrylamide gels. The high homogeneity of the protein enabled large crystals (approx. 1.2 x 0.3 x 0.3 mm) to be prepared, which diffracted to high resolution. The structures of the IL-4 variants T13D (max. resolution 1.65 A), F82D (max. resolution 1.7A) and T13D-F82D (max. resolution 1.8A) were refined on the basis of the structure of wild-type IL-4 (max. resolution 1.8A); all crystals were obtained under identical conditions, allowing detailed comparison. The overall structure of IL-4 comprises the known four-helical bundle in up-up-down-down topology (Fig. 1c) [24,26,27,31,38], which like the crystal packing is unaffected by these mutations. The r.m.s. deviation for the protein backbone is less than 0.5A. The only differences that can be observed between the structures of IL-4 (Fig. 3a) and these three variants (Figs. 3b-d) are located in very close proximity to the site of mutation.
###end p 22
###begin p 23
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Small structural changes probably account for super-agonist binding properties</bold>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 227 231 227 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs </sub>
###xml 233 234 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 234 239 234 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
Small structural changes probably account for super-agonist binding properties. Figures a-d are presented as wall-eyed stereo images. (a) Magnification (stereo image) of the region around Thr13 and Phe82 of wild type IL-4, a 2Fobs - Fcalc electron density map is shown at a level of 1.5sigma. (b) The same area is shown for the super-agonistic IL-4 variant T13D; the exchange of Thr13 for an aspartate leads to a change in side chain conformation of Arg85, which exhibits a bi-dentate hydrogen bond between the carboxylate group of Asp13 and the guanidinium group of Arg85. (c) Area shown for the super-agonist IL-4 F82D; as in (b) a hydrogen bond between Asp82 and Arg85 leads to a change in side chain conformation of Arg85. However, two alternative side chain conformations can be observed for Arg85, one that is "bound" to Asp82 and a second where the Arg85 side chain is oriented towards the solvent. (d) The double variant IL-4 T13D/F82D shows similar side chain orientations to those in IL-4 F82D, but only a single side chain conformation is observed for Arg85.
###end p 23
###begin p 24
###xml 95 96 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 250 251 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 306 308 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 990 992 966 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1127 1129 1089 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1213 1215 1167 1169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1287 1289 1233 1235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1356 1358 1290 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1400 1402 1328 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1805 1807 1733 1735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1828 1832 1756 1757 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</sub>
###xml 1864 1865 1789 1790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1959 1960 1884 1885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
In the variant T13D, the aspartate residue resides in the middle of the first alpha-helix alphaA, and the side chain is oriented towards alpha-helix C. Both carboxylate oxygens of Asp13 are involved in a bi-dentate salt bridge to Arg85 on helix alphac, thereby tightly fixing the side chain of Arg85 (Fig. 3b). The geometries and distances of the bi-dentate hydrogen bonds are close to ideal parameters; the planes formed by the carboxylate of Asp13 and the guanidinium group of Arg85 are out of planarity by just 14degrees; the lengths of the two hydrogen bonds are 2.7 and 2.8A. For comparison, in the structure of wild-type IL-4, the hydroxyl group of Thr13 is hydrogen-bonded to the main chain carbonyl of Glu9; the side chain of Arg85 is moved outward towards the solvent and fixed to the hydroxyl group of Thr13 by a water-mediated H-bond. The change in side chain conformation of Arg85 becomes clear if the side chain torsion angles of the wild-type and variant are compared. The chi1 torsion angle of Arg85 is in the trans conformation (174degrees IL-4, 176degrees IL-4 T13D) for both proteins; in the case of IL-4, chi2 of Arg85 is slightly off trans (160degrees), whereas for T13D, the torsion angle chi2 of Arg85 is in the trans conformation (176degrees). In contrast, the chi3 torsion angle differs by 115degrees between IL-4 (58degrees, gauche- conformation) and T13D (-57degrees, gauche+ conformation). In the lower resolution structures of IL-4 (PDB entries , ) the temperature factors for the side chain atoms of Arg85 were elevated compared to the main chain atoms, indicating greater side chain flexibility. In contrast, in our current study, the temperature factors for the side chain atoms of Arg85 are of similar magnitude in the high-resolution structures of wild-type IL-4 (mean 23A2 for side chain from Cbeta) and its variant T13D (mean 20A2). These values are also close to those of the atoms located in the hydrophobic core (mean 15A2), therefore the side chain of Arg85 can be considered rigid.
###end p 24
###begin p 25
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 126 128 124 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 135 137 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 658 660 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 865 867 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
The structure of the super-agonist variant F82D shows a different picture (Fig. 3c); the side chain conformation, i.e. the chi1 and chi2 torsion angles, of Asp82 is identical to that of the wild-type Phe82. As in IL-4 T13D, the only structural changes are close to the site of mutation. Again the orientation of the side chain of Arg85 is changed from that in IL-4, but the side chain conformations of Arg85 are different in T13D and F82D. Interestingly, the high-resolution structure of variant F82D reveals two alternative side chain conformations for Arg85. In one, the side chain is not hydrogen-bonded to the Asp residue introduced at position 82 (Fig. 3c) and is oriented towards the solvent. In the second, the side chain interacts with the carboxylate group of Asp82 via a weak single hydrogen bond, but it is much less fixed than in the variant T13D (Fig. 3b). The distance between the amino group of Arg85 and the carboxylate group of Asp82 is 3.2A and therefore close to the exclusion criterion for a hydrogen bond. In addition, the temperature factors of the Arg85 side chain atoms are elevated compared to those of rigid main chain or side chain atoms in the variant F82D, indicating that the stabilization of a certain side chain conformation is not as rigid as in variant T13D.
###end p 25
###begin p 26
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
In the case of the double variant, T13D-F82D, the side chain of Arg85 also occupies a different side chain conformation from that in wild-type IL-4. Although two "acceptor" carboxylate groups are present, Asp13 and Asp82, the side chain of Arg85 exhibits only one defined side chain conformation in which the guanidinium group is hydrogen bonded to the carboxylate group of Asp82 (Fig. 3d). As in variant F82D, the temperature factors of the side chain atoms of Arg85 are elevated compared to main chain atoms. The fixation of the side chain of Arg85 to the core structure of IL-4 might therefore be not as strong as observed for T13D. Although only a single defined side chain conformation for Arg85 is observed in T13D-F82D, the loss in affinity of the double variant compared to both super-agonists might result from a competition between two possible side chain conformations of Arg85.
###end p 26
###begin title 27
Interaction analysis using IL-4 receptor variants
###end title 27
###begin p 28
###xml 448 452 436 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 1345 1346 1309 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The binding behaviour of the super-agonists suggests that additional interactions are formed between the ligand and the IL-4 receptor alpha-chain. To determine whether these interactions are formed directly between the substituted side chains of T13D or F82D or result from indirect interaction, we used variants of IL-4Ralpha to identify the potential interaction partners of Asp13 (T13D) and Asp82 (F82D). Single amino acid variants of IL-4RalphaECD were immobilized on a BIAcore CM5 biosensor chip similar to the one described above. Four IL-4Ralpha variants were chosen on the basis of the location of the respective side chain in the ligand-receptor interface. The IL-4Ralpha variant Y13F was selected as a control because the hydroxyl group of Tyr13 is located far from the site of mutation of the two super-agonists T13D and F82D (distance: Asp13 or Phe82 side chain of T13D and F82D - IL-4Ralpha Tyr13 = 10A). Therefore, the effect of the IL-4Ralpha Y13F mutation on the affinity for ligand should be identical in magnitude for wild-type IL-4 and both super-agonistic variants T13D and F82D. In fact, the affinity of IL-4Ralpha Y13F to wild-type IL-4 is reduced by a factor of ~ 20 compared to wild-type IL-4Ralpha. The affinities for the super-agonists T13D and F82D are decreased similarly by factors of 33 and 19, respectively (Table 3).
###end p 28
###begin p 29
Processing and refinement statistics for IL-4 and variants
###end p 29
###begin p 30
BIAcore analysis of IL-4Ralpha variants
###end p 30
###begin p 31
###xml 77 81 73 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
Association and dissociation rates of IL-4 variants to immobilized IL4-RalphaECD variants were measured on a BIA2000 system. The rate constants represent mean values of 12 independent measurements with 6 different analyte concentrations.
###end p 31
###begin p 32
###xml 1142 1143 1102 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The other three IL-4Ralpha variants either carry mutations close to the interacting site or the substituted residues interact directly with the side chains of Thr13 or Phe82 in the ligand. The carboxylate group of IL-4Ralpha Asp67 forms a bi-dentate hydrogen bond with the guanidinium group of IL-4 Arg85, therefore mutation of IL-4Ralpha Asp67 to Ala markedly decreases the binding affinity (IL-4Ralpha D67A : IL-4 ~ 60-fold). In comparison, the affinity of IL-4Ralpha D67A for the super-agonist T13D is only reduced 19-fold, compared to 34-fold for F82D. Aspartate 125 of IL-4Ralpha interacts with the side chains Gln78 and Arg81 of IL-4 and is in close proximity to residue Phe82 of IL-4. Mutation of Asp125 to alanine in IL-4Ralpha reduces the binding affinity to IL-4 8-fold, owing to the loss of two hydrogen bonds formed between the carboxylate group of IL-4Ralpha Asp125 and the side chain amino group of IL-4 Gln78 and the guanidinium group of IL-4 Arg81. For the IL-4 variant T13D, the affinity to IL-4Ralpha D125A is decreased by a factor of 5; for IL-4 F82D, the affinity is reduced 8-fold compared to wild-type IL-4Ralpha (Table 3). Finally, the IL-4Ralpha variant Y127F was tested for binding to IL-4, T13D and F82D. The hydroxyl group of Tyr127 is involved in a hydrogen bond with Thr13 of IL-4. Substitution of IL-4Ralpha Tyr127 with a phenylalanine leads to only a small (2-fold) reduction in binding. A slightly larger reduction in binding affinity is observed for the IL-4 super-agonists T13D (4.5-fold) and F82D (2.5-fold).
###end p 32
###begin p 33
###xml 829 833 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a-c</xref>
Interestingly, none of the IL-4Ralpha variants showed a strong cooperative change in binding affinity for the IL-4 super-agonist T13D and F82D when compared to wild-type IL-4, suggesting that the additional interactions between T13D-F82D and IL-4Ralpha are not formed directly between Asp13 or Asp82 and any of the IL-4Ralpha side chains investigated here. The greatest difference in binding characteristics between wild-type IL-4 and the super-agonist T13D was observed for the IL-4Ralpha variant D67A. Since the side chain of IL-4Ralpha Asp67 is hydrogen-bonded to IL-4 Arg85, this suggests that the side chain of Arg85 is involved in different interactions in the ligand-receptor complexes of wild-type IL-4 and T13D. The differences in side chain orientation of Arg85 between the structures of free IL-4, T13D and F82D (Fig. 3a-c) might therefore also be present in the IL-4 ligand-receptor complexes.
###end p 33
###begin title 34
Homology modelling of IL-4 ligand-receptor interaction
###end title 34
###begin p 35
Unfortunately, we have not succeeded so far in obtaining diffracting crystals for the ligand-receptor complexes comprising the IL-4 super-agonists T13D and F82D bound to the extracellular domain of IL-4Ralpha. In order to obtain insights into the possible interaction mechanism, we have modelled the interaction of T13D and F82D with IL-4Ralpha on the basis of the crystal structure of wild-type IL-4. The changes observed in the structures of the free IL-4 super-agonists T13D and F82D were transferred on to the complex structure by superimposing the free structures of the ligand on to the IL-4 bound to IL-4Ralpha. To obtain the model of the T13D-IL-4Ralpha complex, the coordinates of Asp13 (of T13D) and of Arg85 were used instead of the coordinates of the original residues Thr13 and Arg85 of wild-type IL-4. The same procedure was used for the complex of F82D-IL-4Ralpha. The amino acid exchanges did not cause bad van der Waals contacts, nor was the packing of the side chains in the interface impaired.
###end p 35
###begin p 36
###xml 136 138 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 254 256 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 597 599 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 705 707 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 870 872 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 1095 1097 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
The structure of the complex of wild-type IL-4 bound to IL-4Ralpha shows that the ligand-receptor interface has a modular architecture [33], which, from analysis of the hydrogen bonding, can be described by three independently interacting clusters (Fig. 4a). Two of these three clusters include the so-called main binding determinants, Glu9 (IL-4) and Arg88 (IL-4), which contribute about 80% of the total binding energy. Cluster I is centred on Glu9 of IL-4, which makes several hydrogen bonds with Tyr13 (hydroxyl group), Ser70 (main chain amide) and Tyr183 (hydroxyl group) of IL-4Ralpha (Fig. 4b). Cluster II involves Arg88 of IL-4, which forms a bi-dentate salt bridge with Asp72 of IL-4Ralpha (Fig. 4c). Cluster III consists of the positively charged residues Arg81 and Arg85 of IL-4 and the negatively charged residues Asp66, Asp67 and Asp125 of IL-4Ralpha (Fig. 4d). Although the charged amino acids in Cluster III of the ligand are distributed in a highly complementary manner, these residues do not contribute to the binding affinity, as was shown by mutagenesis and BIAcore analysis [39]. Arg81 and Arg85 of IL-4 form several hydrogen bonds with residues of IL-4Ralpha; however, these interactions do not seem productive.
###end p 36
###begin p 37
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Modular interface of the IL-4 &#8211; IL-4 receptor interaction</bold>
###xml 448 450 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 472 475 464 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 498 500 486 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 522 525 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 548 550 532 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 588 590 568 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
Modular interface of the IL-4 - IL-4 receptor interaction. (a) The interface between IL-4 and IL-4Ralpha consists of three clusters that contribute binding free energy independently of each other. Hydrogen bonding only occurs within one particular cluster but does not extend between two different clusters. Color coding represents the binding free energy that each residue contributes to the ligand-receptor interaction (red: DeltaG = 3.5 kcal mol-1; orange: 3.5 kcal mol-1 > DeltaG = 1.7 kcal mol-1; yellow: 1.6 kcal mol-1 > DeltaG = 0.5 kcal mol-1; dark grey: 0.5 > DeltaG > 0 kcal mol-1. (b) Cluster I is centred on Glu9 of IL-4, which is one of the two main binding determinants of the IL-4 - IL-4Ralpha interaction. (c) IL-4 Arg88 is the central residue in cluster II forming a bi-dentate saltbridge with IL-4Ralpha Asp72. (d) Cluster III consists of a hydrogen-bonding network comprising positively charged residues on the IL-4 interface (Arg81, Arg85) and negatively charged residues on the IL-4Ralpha epitope (Asp67, Asp125).
###end p 37
###begin p 38
###xml 203 205 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 285 287 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
Modelling of the interaction of T13D bound to IL-4Ralpha suggests that the guanidinium group of Arg85 (T13D) now forms bi-dentate hydrogen bonds with the main chain carbonyl of the receptor Asp125 (Fig. 5b). In contrast to the hydrogen-bonding network of Arg85 in wild-type IL-4 (Fig. 5a), Arg85 in the complex of T13D:IL-4Ralpha is probably also fixed to Asp13 (T13D) via a bi-dentate salt bridge. This internal hydrogen bonding would result in fixation of the Arg85 side chain prior to complex formation. Therefore, the conformational entropy is not decreased for Arg85 in the formation of the T13D-IL-4Ralpha complex, whereas for wild-type IL-4 the side chain of Arg85 becomes ordered only upon binding to IL-4Ralpha. Consequently, the entropy cost for immobilizing this side chain neutralizes the energy release of its hydrogen bonding interactions.
###end p 38
###begin p 39
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hydrogen bonds network in the IL-4 &#8211; IL-4 receptor interface</bold>
Hydrogen bonds network in the IL-4 - IL-4 receptor interface. (a) The hydrogen bond network in cluster III (stippled lines in cyan) between wild type IL-4 and IL-4Ralpha is shown. Arg85 of IL-4 is H-bonded to residues of IL-4Ralpha (Asp67 side chain, Asp125 main chain), but several of these H-bonds are mediated via solvent molecules. (b) Model for the interaction of the super-agonist IL-4 T13D with IL-4Ralpha. The "internal" H-bonds between Asp13 and Arg85 orient the side chain of Arg85 to yield intermolecular H-bonds to the IL-4Ralpha Asp125 main chain carbonyl. (c) A similar mechanism as in (b) can be drawn for the IL-4 F82D variant when an intramolecular H-bond between IL-4 Asp82 and Arg85 is assumed.
###end p 39
###begin p 40
###xml 157 159 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 545 547 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
The model of the F82D:IL-4Ralpha complex allows us to propose a stabilizing mechanism similar to that suggested for the complex of T13D and IL-4Ralpha (Fig. 5c). Here, too, the carboxylate group of Asp82 (F82D) forms a bi-dentate salt bridge with the guanidinium group of Arg85, thereby immobilizing the side chain of Arg85 in the ligand-receptor interface. The "head groups", i.e. the two imino groups, form two hydrogen-bonds with the main chain carbonyl of Asp125 (IL-4Ralpha), as also observed in the model of T13D bound to IL-4Ralpha (Fig. 5b). Hence the two amino acid changes in T13D and F82D lead to an identical change in the side chain conformation of Arg85 (ligand). This change of Arg85 subsequently transduces the additional stabilization/interaction observed for the two super-agonists. Since the additional interaction is mediated in both super-agonists by the same indirect mechanism via Arg85, this also explains why combination of two super-agonistic mutations did not lead to a further increase in binding affinity.
###end p 40
###begin title 41
A change in side chain conformation of IL-4 Arg85 leads to an increase in binding affinity
###end title 41
###begin p 42
###xml 530 531 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 531 533 523 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 540 541 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 541 543 533 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 594 596 578 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 722 724 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 726 728 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 1078 1080 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 1195 1196 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1196 1200 1176 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off </sub>
###xml 1227 1228 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1228 1232 1208 1212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off </sub>
###xml 1413 1415 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1536 1537 1516 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1537 1541 1517 1521 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off </sub>
###xml 1553 1554 1533 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1554 1558 1534 1538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off </sub>
We tested the interaction model proposed above by mutating Arg85 of IL-4 and the super-agonistic variants to alanine and measuring the residual binding affinity to IL-4Ralpha. If Arg85 is really involved in generating the additional stability/interaction, then, owing to cooperativity, mutation of this residue would have a greater effect in the super-agonistic variants (decrease in binding affinity) compared to wild-type IL-4. Changing Arg85 of IL-4 to alanine does not change the binding affinity for IL-4Ralpha dramatically (KD (R85A)/KD (wt IL-4) ~ 4.7-fold, thus DeltaDeltaG = 1 kcal mol-1). This is in line with the observation that residues in Cluster III do not generally contribute to the overall binding (Fig. 4a, 6a). In particular, the dissociation rate constant is only increased by a factor less than 1.3, showing that the hydrogen-bonding network of Arg85 with IL-4Ralpha provides no free binding energy. In contrast, the affinity of the IL-4 variant T13D-R85A is decreased 6.5-fold and its dissociation rate reflects IL-4 wild-type-like binding kinetics (Fig. 6a). Since the hallmark of the super-agonistic variants was a clearly decreased dissociation rate constant (relative koff (T13D or F82D) = 0.3 - 0.4 koff (IL-4wt)), this confirms the above mechanism by which Arg85 is involved in generating the higher binding affinity. An even bigger effect is observed for the variant F82D-R85A (Fig. 6b). Here the equilibrium binding constant is increased almost 36-fold, mainly because of the increased dissociation rate (koff (F82D-R85A)/koff (F82D) ~ 9). To exclude the possibility that structural changes in addition to the removal of the Arg85 side chain play a role in the changes in binding stability, we determined the structures of the IL-4 variants R85A, T13D-R85A and F82D-R85A. No changes in the local structure around residues Thr/Asp13, Phe/Asp82 or Arg85 could be observed (data not shown).
###end p 42
###begin p 43
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Arg85 is involved in the binding mechanism of the IL-4 super-agonist T13D and F82D</bold>
###xml 245 248 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 330 331 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 331 334 327 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
Arg85 is involved in the binding mechanism of the IL-4 super-agonist T13D and F82D. BIAcore sensorgrams of ligand-receptor interactions. Solutions of IL-4 variants (concentration 10 nM) were perfused over a sensor chip with immobilized IL4RalphaECD. (a) The variant IL4-T13D-R85A (green) shows a similar "fast" dissociation rate (koff) as wild-type IL-4 (blue); the binding kinetics of the super-agonist IL4-T13D are shown in red for comparison. (b) As for T13DR85A, the variant F82DR85A (magenta) exhibits a fast dissociation rate compared to the super-agonistic single amino acid variant IL4-F82D (orange). However, the dissociation is even faster than wild-type IL4 (blue).
###end p 43
###begin title 44
IL-13 utilizes the same main binding determinants for binding to IL-4Ralpha
###end title 44
###begin p 45
###xml 119 121 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 122 124 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 305 306 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 306 308 294 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 357 359 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 523 525 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 526 527 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 553 554 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 554 556 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 666 667 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 819 821 787 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 838 839 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 839 841 803 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 970 972 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 973 975 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1190 1193 1133 1136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 1358 1360 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1361 1363 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1364 1366 1307 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1367 1369 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1370 1372 1313 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1385 1387 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1388 1390 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1780 1784 1703 1707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 1813 1817 1732 1736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2164 2166 2077 2079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2482 2486 2383 2387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2528 2529 2429 2430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 2529 2531 2430 2432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 2587 2591 2484 2488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2633 2634 2530 2531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 2634 2636 2531 2533 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 2661 2665 2553 2557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2709 2712 2597 2600 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 2807 2811 2691 2695 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2812 2813 2696 2697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 2813 2815 2697 2699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 2838 2842 2718 2722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2843 2844 2723 2724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 2844 2846 2724 2726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 2875 2879 2751 2755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 3013 3017 2885 2889 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 3023 3025 2895 2897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 3077 3081 2945 2949 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 3136 3140 3000 3004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 3556 3558 3416 3418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
IL-13 uses the same cellular receptor for signalling as IL-4, consisting of the IL-4Ralpha and IL-13Ralpha 1 subunits [40,41]. However, the binding mechanism is different and the order of the binding events is reversed. IL-13 binds first with moderate to high affinity to its IL-13Ralpha1 receptor chain (KD ~ 25 nM) as determined from BIAcore experiments [42]. Then the second subunit is recruited into the complex. In contrast to IL-4, only one "low-affinity" chain, i.e. IL-4Ralpha, is able to bind to the complex (Fig. 1b,7). The apparent affinity (KD ~ 80 nM) of the extracellular domain of IL-4Ralpha to the binary complex of IL-13 bound to IL-13Ralpha1 (Fig. 7) is rather high compared to the low apparent binding affinities observed for the interaction of the binary complex of IL-4:IL-4Ralpha with either gammac or IL-13Ralpha1 (KD ~ 2 to 5 muM). The binding sites for IL-13Ralpha1 and IL-4Ralpha on IL-13 have been mapped by mutagenesis and functional assays [35,37]. The binding epitope for IL-13Ralpha1 is located on the C-terminal end of helix D of IL-13; the epitope for the IL-4Ralpha is located on the helices A and D. The two main binding determinants of IL-4 to IL-4RalphaECD, i.e. Glu9 and Arg88, map to the residues Glu11 and Arg64 of IL-13 (numbering according to the mature part of SWISS-PROT entry P35225) when the structures of IL-4 [24,26,27,31,38] and IL-13 [22,23] are superimposed. Both IL-13 variant proteins, E11A and R64A, were prepared and their binding properties for the ECDs of IL-13Ralpha1 and IL-4Ralpha were determined by BIAcore analysis. The binding affinities of both variants to IL-13Ralpha1 were unchanged compared to wild-type IL-13 (data not shown). Binding to IL-4Ralpha was measured by binding IL-13 first to immobilized IL-13Ralpha1ECD and then perfusing IL-4RalphaECD together with IL-13 over this binary complex. The apparent binding affinities were 35 muM and 200 muM for IL-13 E11A and IL-13 R64A, respectively. The dramatic loss in affinity clearly indicates the requirement of both residues for binding of IL-13 to IL-4Ralpha, which has also been shown previously in a more qualitative cell-based measurement [37]. Compared with the apparent affinity of wild-type IL-13, the affinity drops by factors of 230 and 1300 for IL-13 E11A and IL-13 R64A, showing that although the affinity of IL-13 for IL-4Ralpha is 1000-fold lower than that of IL-4 for IL-4Ralpha, both main binding determinants are conserved. Remarkably, IL-4RalphaECD is bound with a relatively high affinity (KD = 80 nM) to the binary complex of IL-13 and IL-13Ralpha1ECD compared to the low-affinity interaction (KD ~ 2 muM) of IL-13Ralpha 1ECD to the binary complex of IL-4 and IL-4RalphaECD. Although this suggests that the affinities of IL-13 to the two receptor subunits IL-13Ralpha1ECD (KD ~ 25 nM) and IL-4RalphaECD (KD ~ 80 nM to IL-13-IL-13Ralpha1ECD complex) are of similar magnitude, the binding mechanism is still absolutely sequential, since IL-13 alone does not bind to IL-4RalphaECD (Fig. 1b). This clearly shows that the binding of IL-4RalphaECD to the binary complex comprising IL-13 and IL-13Ralpha1ECD is highly cooperative and probably involves a large receptor-receptor interface. The cooperative binding mechanism of the IL-13 ligand-receptor interaction is quite different from that of IL-4; here the overall binding affinity is dominated by the interaction of IL-4 with its high-affinity receptor subunit IL-4Ralpha; the low-affinity interactions do not add significantly to the overall binding free energy (Fig. 1a).
###end p 45
###begin p 46
###xml 0 85 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BIAcore analysis of interaction between IL4-R&#945; and the IL-13/IL13-R&#945;1 complex</bold>
###xml 269 273 248 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 376 380 347 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 589 590 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 590 592 552 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
BIAcore analysis of interaction between IL4-Ralpha and the IL-13/IL13-Ralpha1 complex. BIAcore sensorgrams of the interaction between IL-4Ralpha and the binary complex of IL-13 and IL13-Ralpha1. IL-13 (1 muM) is perfused over a sensor chip with immobilized IL-13Ralpha1ECD to form a binary complex. After saturation of the immobilized IL13Ralpha1 chains with IL-13, IL4-RalphaECD (concentrations 1, 2.5, 5, 7.5, 10 muM) is perfused over the binary complex to measure the binding of the IL4-Ralpha chain to the complex of IL-13 and the IL13Ralpha1 chain. The apparent dissociation constant KD of approx. 150 nM for the binding of the IL4Ra chain to the binary complex was calculated by evaluating dose dependency of equilibrium binding.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 306 307 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
In this publication we provide a molecular mechanism by which the two IL-4 super-agonistic variants T13D and F82D bind to the extracellular domain of the IL-4Ralpha receptor with higher affinities than wild-type IL-4. The binding affinity for IL-4Ralpha of both variants is increased roughly 3-fold (Table 1). Structural analysis revealed that changes are limited to the very local environment around the site of mutation. A homology model of the ligand-receptor interaction was built, since attempts to crystallize complexes between the super-agonistic variants and the extracellular domain of the IL-4 receptor alpha have not so far been successful. The data clearly suggest that the concept of a modular protein-protein interface might allow binding affinity and specificity to be varied independently.
###end p 48
###begin p 49
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1360 1362 1360 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1978 1980 1978 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1981 1983 1981 1983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 2100 2102 2100 2102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 2265 2267 2265 2267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 2268 2270 2268 2270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 2555 2557 2555 2557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 2295 2300 <span type="species:ncbi:9606">human</span>
The "key-lock" principle used in the past to describe protein-protein interactions is based on the assumption that rigid molecules interact on the basis of surface geometry complementarities. This strict requirement would very probably result in monospecific interactions, i.e. only one molecule binds to another single molecule. However, cross-reactivity in antibody-antigen interactions showed early on that molecular recognition is much less specific. Nowadays many proteins, e.g. growth factors/-receptors, hormones, etc., or protein domains, have been shown to have multiple interaction partners that share limited sequence and possibly structural homology [43-48]. In the cytokine superfamily, the so-called redundant functions exhibited by many cytokines indicate the sharing of one or more receptor subunits, although sequence similarity is frequently below 25% within a superfamily [49]. This leads to the question how proteins generate binding affinity and binding specificity [50]. This question is difficult to answer, since what makes an interaction epitope is still largely unknown. Attempts to find common characteristics for protein-protein recognition sites have only been moderately successful, since the average binding epitope of a large compilation of protein-protein interfaces is almost indistinguishable from a regular protein surface [51]. It rather seems that there is a clear difference between the chemical and geometrical composition of a binding site and the regular surface if the binding versus non-binding sites are compared on a single protein. Nevertheless, computational analyses of protein-protein complexes have yielded some fruitful insights into the general characteristics of interaction interfaces. First, the degree of amino acid sequence conservation is increased within binding epitopes; secondly, the interfaces on two binding partners seem to be coupled in evolution, and thus can be used to predict binding epitopes and partners [52,53]. Furthermore, certain amino acids seem to be enriched in protein-protein interfaces (i.e. Arg, aromatic residues) [51]. A mechanism explaining how binding affinity is modulated on large protein epitopes was introduced by the concept of a binding hot spot by Cunningham and Wells [54,55]. Functional studies on human growth hormone showed that only a few residues within a rather large epitope generate the majority of the binding free energy; however, residues that are "non-productive" in terms of the generation of binding affinity might be important for specificity [56].
###end p 49
###begin p 50
###xml 284 285 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c</sub>
###xml 324 326 304 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 366 368 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 417 419 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 767 768 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 768 770 736 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 933 935 892 894 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1127 1129 1078 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1273 1275 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1276 1278 1223 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1543 1545 1475 1477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 2180 2182 2104 2106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 2200 2202 2120 2122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 2254 2256 2174 2176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 3296 3298 3204 3206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 3299 3301 3207 3209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 3807 3810 3711 3714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">11 </sup>
###xml 3815 3816 3719 3720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3941 3942 3845 3846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 3942 3944 3846 3848 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
The IL-4/IL-13 receptor system represents an extreme model of ligand-receptor promiscuity, since both ligands, i.e. IL-4 and IL-13, can bind to the same cellular receptor consisting of the IL-4Ralpha and the IL-13Ralpha1 receptor subunits. Two further subunits, IL-13Ralpha2 and gammac, seem to be ligand-specific: the gammac subunit binds to IL-4 but not to IL-13 [40] while IL-13Ralpha2 binds exclusively to IL-13 [57]. Despite the use of an identical receptor, the binding mechanisms for the two ligands differ, and the binding affinities between the individual ligand and receptor proteins vary dramatically (by a factor of 200-1000). One ligand usually interacts with one receptor subunit (i.e. IL-4 with IL-4Ralpha, IL-13 with IL-13Ralpha1) with high affinity (KD ~ 90 - 150pM for IL-4, ~ 20 - 30 nM for IL-13), but the other subunit is bound with lower affinity, usually in the high nM to muM range (e.g. IL-13Ralpha1 or gammac to the binary complex of IL-4 and IL-4Ralpha). This requires adjustment of the binding strength of the receptor subunits over a large bandwidth, but the specificity must remain high. The gammac receptor subunit is also shared among the cytokines IL-2, -4, -7, -9, -15 and -21 and can be bound by IL-4 instead of the IL-13Ralpha1 subunit [40,58]. However, this subunit always interacts as a low-affinity receptor chain with the binary complexes of the above-listed cytokines with their respective high-affinity receptor subunits, i.e. IL-2Rbeta, IL-4Ralpha, IL-7Ralpha. Hence, the low specificity of the gammac receptor subunit might be a direct result of only low-affinity binding. The specificities of IL-4Ralpha and IL-13Ralpha1 for both ligands IL-4 and IL-13 are high; both receptor subunits only recognize IL-4 and IL-13 despite the low sequence identity between the two ligands and highly variable affinities. One possible mechanism by which different affinities for binding partners can be provided by a single protein involves the use of different epitopes or different subsets of residues within an overlapping epitope. Such mechanisms have been discussed for the binding of the common signal transducer chain gp130 in the IL-6 system [59]. Also, the gammac chain binds to IL-4 and IL-21 via such a mechanism [60]. However, these are different from the IL-4/IL-13 system, as their epitopes do not contain the modular architecture formed by several independent acting hot spots. The usage of one, two or all three hot spots in the IL-4/IL-4Ralpha interface allows the affinity to be scaled from high the nM to the pM range. Even if one of the hot spots is not "used" for binding, i.e. in terms of generating a significant contribution to the binding free energy, the non-contributor might be used to ensure specificity of interaction. According to this mechanism, we assume that all three hot spots are used for binding of the IL-4 super-agonist proteins, while only hot spots 1 and 2 are used in optimal form for wild-type IL-4 and hot spot 3 only contributes marginally. For binding of IL-4Ralpha to the binary complex of IL-13 and IL-13Ralpha1, only two hot spots are probably involved. For the interaction of different colicin endonucleases (E DNase) and the immunity proteins (Im), a similar mechanism termed "dual recognition" has been described [61,62]. Here, two epitopes/hot spots in close proximity (residing on different secondary structure elements) are used to generate binding affinity and specificity. One binding hot spot formed by three consecutive residues is used to generate a "basal" binding affinity, and the second epitope/hot spot adds additional affinity for cognate partners or is silent for non-cognate binding partners, as in our observation on the modular IL-4/IL-4Ralpha interface. The differences in affinities seem rather large - 1011 to 105-fold - owing to the very high affinities in this system. Even many non-cognate partners still bind with high affinity, e.g. KD ~ 1 to 100 nM range, which is comparable to the high-affinity interactions in the IL-4/-13 system.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 1391 1393 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1394 1396 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1467 1469 1455 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1470 1472 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
Analyses of the modular architecture of the IL-4 - IL-4Ralpha interface yield a possible mechanism by which proteins might be able to generate binding affinity and specificity independently. Affinity and specificity were often considered to be linked, i.e. high specificity requires high affinity and vice versa. However, the binding affinities of IL-4 and IL-13 to IL-4Ralpha differ by a factor of more than 1000, but binding specificity remains absolutely high since the receptor subunit IL-4Ralpha binds exclusively to IL-4 and IL-13. Such an interface formed by several interaction clusters/hot spots of binding allows for a broad range of affinities by selecting how many of these interaction clusters contribute to the overall binding free energy. Non-contributing clusters will, however, still be important for the specificity of the interaction. Understanding how proteins generate affinity and specificity is especially important as more and more growth factor receptor families are found to show promiscuous binding to their respective ligands. However, this limited specificity is not always accompanied by low binding affinities. Knowledge of the details of the recognition mechanism will finally allow highly specific growth factors to be designed that are able to distinguish between different receptor combinations, as shown for the T-cell specific IL-4 antagonist IL-4R121E [63,64] or the IL-13 cytotoxin fusion used for treatment of several cancers [65,66].
###end p 52
###begin title 53
Methods
###end title 53
###begin title 54
Protein expression and purification
###end title 54
###begin p 55
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1424 1426 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1462 1464 1454 1456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1503 1505 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1506 1508 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 338 350 <span type="species:ncbi:511693">E. coli BL21</span>
###xml 1296 1301 <span type="species:ncbi:9606">human</span>
Human IL-4 was cloned into the expression vector pQE-80L (Qiagen) modified to carry a gene encoding kanamycin resistance; human IL-13 was cloned into the expression vector pET-28b (Novagen). Mutations in either IL-4 or IL-13 were introduced using the QuikChange (Stratagene) method. The expression vector constructs were transformed into E. coli BL21(DE3)Star (Stratagene) cells. For purification, cells from 4L cultures were lysed by sonication, and inclusion bodies were extracted and purified by extensive washing steps. Refolding of IL-4 was performed according to published protocols except that PBS buffer (phosphate buffered saline) pH 7.4 was used for dialysis [67]. Refolded IL-4 was purified by two cation exchange chromatography steps utilizing CM-Sepharose and High-Performance SP-Sepharose (Pharmacia), employing linear NaCl-gradients at pH 5.0 (25 mM acetate buffer) and pH 7.0 (25 mM phosphate buffer), respectively. Refolding of IL-13 followed the protocol published by Eisenmesser et al. [68]. Refolded IL-13 was purified by cation exchange chromatography using SP-Sepharose Fast Flow at pH 6.1 (25 mM phosphate buffer, 10 mM NaCl, 1 mM EDTA) and subsequently by RP-HPLC using a C4 Vydac column employing a linear gradient of 0-100% acetonitrile. The extracellular domain of the human IL-4 receptor alpha was expressed and purified from baculovirus infected Sf9 insect cell culture as described previously [19]. The receptor ectodomains of gammac and IL-21R were prepared as described [20,60].
###end p 55
###begin title 56
Proliferation assays
###end title 56
###begin p 57
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 249 252 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 459 461 459 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 491 494 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 136 141 <span type="species:ncbi:9606">human</span>
The bioactivities of IL-4 wild-type and variant proteins and of IL-13 were determined by measuring [3H]thymidine incorporation into the human premyeloid cell line TF-1 [69,70]. Cells were cultured in RPMI medium supplemented with 10% FBS and 2 ng ml-1 recombinant GM-CSF. Cells were washed twice with PBS and seeded at a concentration of 5 x 103 cells/well in 96 well plates in RPMI medium without GM-CSF. Varying concentrations of IL-4 or IL-13 proteins (log3 dilutions starting at 1 mug ml-1 as the highest concentration) were added, and the cells were cultured for 48 h. Tritiated thymidine (Amersham, 0.25 muCi/well) was added to each well 8 h before the plates were harvested using a Skatron cell harvester (Skatron Inc., USA). Filter mats were counted in a beta plate counter. All experiments were performed in triplicate. Half-maximal responses of IL-4 and IL-4 super-agonist proteins in TF-1 cells were at approx. 10+/- 8 pM; for IL-13 the half-maximal response was observed at a concentration of 600+/- 200 pM.
###end p 57
###begin title 58
Crystallization of IL-4 and variants
###end title 58
###begin p 59
###xml 118 119 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 120 121 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 200 203 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 281 282 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 284 286 284 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 498 499 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 500 501 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 503 504 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 613 615 607 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IL-4 and variants thereof were further purified for crystallization by ammonium sulfate precipitation. Solid (NH4)2SO4 was added to a concentration of 1.2 M to solutions of approx. 10 - 15 mg ml-1 protein. Precipitated impurities were removed by centrifugation, further (NH4)2SO4 was added to a final concentration of 2.5 M, and the mixture was kept on ice for 15 min. The mixture was centrifuged at 14.000 x g for 15 min at 4degreesC and the precipitated IL-4 was washed twice with 2.5 M (NH4)2SO4. The IL-4 was then dissolved in 1.2 M ammonium sulfate, pH 7.0, at a final protein concentration of 15 mg ml-1.
###end p 59
###begin p 60
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 295 296 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 297 298 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 300 301 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
Crystals of IL-4 and variants were obtained by hanging drop vapor diffusion at room temperature using (NH4)2SO4 concentrations ranging from 1.9 to 2.4 M, and a pH range of 5.0 to 6.5. For measurements at 100 K, 25% glycerol was used as a cryoprotectant. High quality crystals grew from 2.2 M (NH4)2SO4, 0.1 M sodium acetate pH 5.2 and 25% glycerol using a protein concentration of 12 mg ml-1.
###end p 60
###begin title 61
Data collection
###end title 61
###begin p 62
###xml 521 522 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Data for IL-4 or its variants were each obtained from a single crystal at 100 K at different beamlines (X06SA PX at the Swiss Light Source, Switzerland, ID14-1 at the European Synchrotron Radiation Facility, Grenoble, France) or a home source (Rigaku MicroMax007 with Osmic VariMax mirror system). The data were processed and integrated using the software MOSFLM version 6.2.1, and scaling was performed using SCALA CCP4 version 4.2.1; a summary of the processing statistics of the various datasets is presented in Table 2. To test for possible bias introduced by the model structure IL-4 (PDB entry ) used for data interpretation by the molecular replacement method, we also collected a dataset of a SeMet-labeled IL-4 variant F82D at three wavelengths (BW7A, EMBL DESY, Hamburg, Germany) (see Table 4). Structures of the variant F82D refined by the MAD approach and molecular replacement were identical, showing that the model structure 1HIK used as the start structure for refinement did not bias the results of the individual variant structures.
###end p 62
###begin p 63
MAD data set for IL-4 variant F82D
###end p 63
###begin p 64
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
1 number in parentheses indicate highest resolution shell.
###end p 64
###begin p 65
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 3 7 3 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">sym </sub>
###xml 27 30 10 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl</sub>
###xml 32 36 15 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl </sub>
###xml 40 43 23 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl</sub>
###xml 63 66 29 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl</sub>
###xml 68 71 34 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl</sub>
###xml 81 84 47 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">hkl</sub>
2 Rsym = summation operatorhkl|Ihkl - <Ihkl>|summation operatorhkl<Ihkl> where <Ihkl> is the mean intensity of symmetry-related observations of a unique reflection
###end p 65
###begin p 66
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 3 10 3 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cullis </sub>
###xml 49 52 49 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">PH </sub>
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P</sub>
3 Rcullis = <phase-integrated lack of closure>/<FPH - FP>
###end p 66
###begin p 67
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 3 9 3 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Kraut </sub>
###xml 34 35 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P</sub>
###xml 37 38 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 43 45 26 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">PH</sub>
###xml 69 70 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P</sub>
4 RKraut = summation operator |(|FP+FH|)-|FPH|)|/summation operator|FP|
###end p 67
###begin p 68
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 28 29 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 29 30 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 57 58 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
5 Phasing power = (radical|FH2|)/(radical|lack-of-closure2|), (a/c) denote acentric and centric reflections
###end p 68
###begin p 69
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
6 figure of merit is given before and after solvent density modification
###end p 69
###begin title 70
Structure analysis
###end title 70
###begin p 71
###xml 651 653 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 689 691 675 677 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 758 760 738 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 775 777 751 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 809 811 781 783 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 842 844 808 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1369 1370 1335 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1370 1374 1336 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">obs </sub>
###xml 1376 1377 1342 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1377 1382 1343 1348 <sub xmlns:xlink="http://www.w3.org/1999/xlink">calc </sub>
###xml 1632 1633 1598 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The structures of IL-4 and the variants investigated in this study were refined using the lower resolution structure (PDB entry ) as a start model. To minimize possible bias through the start model structure, especially for the ill-defined loop regions, MAD phasing was applied to the IL-4 variant F82D. IL-4 (as well as the variant F82D) contains a single Met residue. The Seleno-Met site was determined and refined using the protocols supplied with the program CNS using a dataset measured at three wavelengths (inflection, peak and remote). The resulting electron density map was used to rebuild the loop regions between the first alpha-helix alphaA and the first short beta-strand beta1 (Glu19 to Cys24) as well as the long loops between beta-strand beta1 and helix alphaB (Lys37 to Glu41) and helix alphac and the second beta-strand beta2 (Ser98 to Glu103). The resulting "improved" model was then used for interpretation of the diffraction data of the individual IL-4 proteins. The program REFMAC5 was used for subsequent refinement, followed by manual rebuilding of the models using the software QUANTA2000 (Accelrys Inc.). One TLS group was defined for the complete IL-4 molecule to account for anisotropy in the data. The progress of refinement was monitored by cross-validation using a test data set comprising 5% of the reflections. In the final refinement, Fobs - Fcalc difference electron density maps were used to identify water molecules as well as sulfate ions resulting from the high concentration of the ammonium sulfate precipitant. The final conventional and free R-factors for each model are presented in Table 2.
###end p 71
###begin title 72
Interaction analysis using BIAcore
###end title 72
###begin p 73
###xml 162 165 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 328 331 313 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD</sub>
###xml 456 458 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 459 461 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 549 553 530 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 679 681 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 682 684 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1106 1107 1087 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1107 1109 1088 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
###xml 1129 1130 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1130 1133 1111 1114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 1294 1295 1275 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1295 1299 1276 1280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off </sub>
###xml 1548 1549 1529 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1549 1551 1530 1532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1577 1578 1558 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 1578 1580 1559 1561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">D </sub>
###xml 1582 1583 1563 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1583 1586 1564 1567 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 1587 1588 1568 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1588 1591 1569 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on </sub>
###xml 1729 1730 1710 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1834 1836 1807 1809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1892 1894 1861 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2216 2220 2174 2178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ECD </sub>
###xml 2405 2407 2355 2357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 2713 2714 2663 2664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Interaction analysis was performed using a BIAcore 2000 system. (Pharmacia Biosensor). All experiments were carried out at 25degreesC at a flow rate of 50 mul min-1 in HBS running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20). The extracellular domain of the IL-4 receptor alpha-chain (IL-4RalphaECD) and variants thereof were biotinylated and immobilized to a streptavidin-coated sensor chip CM5 at a density of 50-120 RU [19,39]. To determine the kinetic rate constants, sensor chips with a low density of IL4RalphaECD were used to minimize rebinding effects. The IL-4 receptor proteins were prepared and analyzed under conditions as described [19,39]. Interaction with IL-4 proteins was measured after regeneration of the chip surface with 4 M magnesium chloride. The sensorgrams were evaluated using the software BIAevaluation version 2.0, assuming a 1:1 interaction. Bulk face effects were corrected by subtracting the control flow cell (FC1) from all sensorgrams; non-specific binding was negligible. The analysis yielded kinetic rate constants for complex formation (kon) and dissociation (koff). The latter were evaluated at near saturating concentrations of analyte during the first 10s of complex dissociation to avoid any effects of the rate constant koff due to rebinding of the dissociating ligand. The apparent binding constant of each variant was obtained using six analyte concentrations (2 - 20 nM). Standard deviations were deduced from 18 independent measurements. Apparent dissociation constants KD were either calculated as KD = koff/kon or by evaluating the dose dependency of equilibrium binding. Mean values together with the mean standard deviation are presented in Table 1. Binding of IL-4 and IL-13 ligand proteins to their low-affinity receptor subunits (IL-13Ralpha1, gammac and IL-4Ralpha) were analyzed by a COINJECT experiment [20]. IL-13 protein (concentration 1 muM) was perfused over a CM5 chip surface coated with the extracellular domain of the IL-13 receptor alpha1-chain to saturate any binding sites fully. Different concentrations (1 - 10 muM in the case of wild-type IL-13 and 5 - 100 muM in the case of IL13-E11A and IL13-R64A) of IL-4RalphaECD were then perfused together with IL-13 ligand by the COINJECT procedure of the BIAcore2000 system. A similar setup was used to measure the low-affinity binding of IL-13Ralpha1 and gammac to IL-4 and its variants. Binding affinities were deduced from these binding experiments by evaluating the dose dependency of equilibrium binding (IL-13 variants) or directly from the binding kinetics (IL-13 wild-type). Binding constants derived from analysis of equilibrium binding are presented in Table 1.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
M. Kraich and M. Klein performed the mutagenesis, protein expression and purification and crystallization of the IL-4 ligand and receptor proteins. E.P. and H.H. participated in the purification of the IL-13 ligand and receptor proteins. J.N. participated in the analysis of the interaction analysis data, W.S. performed the BIAcore measurements and analyses; T.D.M conceived the study and participated in all stages of the work. All authors read and approved the final manuscript.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
###xml 238 240 234 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
We thank M. Gottermeier for excellent technical assistance, A. Kotzsch for help during data acquisition, and M. Buehner for helpful discussions and advice. The authors thank J.-L. Zhang for providing the receptor ectodomain proteins gammac and IL-21R. We thank C. Schulze-Briese and T. Tomizaki from Swiss Light Source for assistance during data acquisition and would like to acknowledge the access to the synchrotron radiation beamline X06SA at the Swiss Light Source (SLS), Switzerland. Datasets for two IL-4 variants were acquired at the beamline ID14 at the European Synchrotron Radiation Facility (ESRF), the MAD dataset for the IL-4 variant F82D was measured at the beamline EMBL BW7, DESY, Hamburg. The authors would like to thank R. Ravelli and P. Tucker for support. This project was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 487 TP B2. We gratefully acknowledge access to the home source x-ray equipment granted by the DFG-funded Virchow Center, Wuerzburg.
###end p 77
###begin p 78
The atomic coordinates and structure factors for the structures of IL-4 and the variants in this study have been deposited with the Protein Data Bank (accession codes 2B8U (IL-4), 2D48 (IL-4T13D), 2B8X (IL-4F82D), 2B8Y (IL-4T13DF82D), 2B8Z (IL-4R85A), 2B90 (IL-4T13DR85A) and 2B91 (IL-4F82DR85A)).
###end p 78
###begin article-title 79
Interleukin-4: a prototypic immunoregulatory lymphokine
###end article-title 79
###begin article-title 80
Lymphocyte responses and cytokines
###end article-title 80
###begin article-title 81
Molecular mechanisms of immunoglobulin E regulation
###end article-title 81
###begin article-title 82
###xml 24 29 <span type="species:ncbi:9606">human</span>
Molecular regulation of human IgE synthesis
###end article-title 82
###begin article-title 83
###xml 36 41 <span type="species:ncbi:9606">human</span>
Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma
###end article-title 83
###begin article-title 84
IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy
###end article-title 84
###begin article-title 85
STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts
###end article-title 85
###begin article-title 86
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression
###end article-title 86
###begin article-title 87
###xml 59 64 <span type="species:ncbi:9606">human</span>
IL-4 enhances proliferation and mediator release in mature human mast cells
###end article-title 87
###begin article-title 88
###xml 34 39 <span type="species:ncbi:9606">human</span>
Basophilic differentiation of the human leukemia cell line KU812 upon treatment with interleukin-4
###end article-title 88
###begin article-title 89
The TH1/TH2 paradigm in allergy
###end article-title 89
###begin article-title 90
The defective gene in X-linked severe combined immunodeficiency encodes a shared interleukin receptor subunit: implications for cytokine pleiotropy and redundancy
###end article-title 90
###begin article-title 91
The common gamma-chain for multiple cytokine receptors
###end article-title 91
###begin article-title 92
###xml 61 66 <span type="species:ncbi:9606">human</span>
A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor
###end article-title 92
###begin article-title 93
###xml 15 20 <span type="species:ncbi:9606">human</span>
Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex
###end article-title 93
###begin article-title 94
The IL-4 receptor: signaling mechanisms and biologic functions
###end article-title 94
###begin article-title 95
###xml 24 29 <span type="species:ncbi:9606">human</span>
Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses
###end article-title 95
###begin article-title 96
###xml 33 38 <span type="species:ncbi:9606">human</span>
Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation
###end article-title 96
###begin article-title 97
Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein
###end article-title 97
###begin article-title 98
The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain
###end article-title 98
###begin article-title 99
Kinetic analysis of the interleukin-13 receptor complex
###end article-title 99
###begin article-title 100
Solution structure of interleukin-13 and insights into receptor engagement
###end article-title 100
###begin article-title 101
###xml 22 27 <span type="species:ncbi:9606">human</span>
Solution structure of human IL-13 and implication for receptor binding
###end article-title 101
###begin article-title 102
###xml 40 45 <span type="species:ncbi:9606">human</span>
Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy
###end article-title 102
###begin article-title 103
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin 4. The solution structure of a four-helix bundle protein
###end article-title 103
###begin article-title 104
###xml 33 38 <span type="species:ncbi:9606">human</span>
Crystal structure of recombinant human interleukin-4
###end article-title 104
###begin article-title 105
###xml 21 26 <span type="species:ncbi:9606">human</span>
Crystal structure of human recombinant interleukin-4 at 2.25 A resolution
###end article-title 105
###begin article-title 106
###xml 136 141 <span type="species:ncbi:9606">human</span>
Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and proliferative activity of human interleukin-4
###end article-title 106
###begin article-title 107
###xml 14 19 <span type="species:ncbi:9606">human</span>
Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement
###end article-title 107
###begin article-title 108
###xml 23 28 <span type="species:ncbi:9606">human</span>
A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor alpha chain
###end article-title 108
###begin article-title 109
Aspects of receptor binding and signalling of interleukin-4 investigated by site-directed mutagenesis and NMR spectroscopy
###end article-title 109
###begin article-title 110
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin-4 and variant R88Q: phasing X-ray diffraction data by molecular replacement using X-ray and nuclear magnetic resonance models
###end article-title 110
###begin article-title 111
Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface
###end article-title 111
###begin article-title 112
Structure, binding, and antagonists in the IL-4/IL-13 receptor system
###end article-title 112
###begin article-title 113
Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine
###end article-title 113
###begin article-title 114
Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution
###end article-title 114
###begin article-title 115
Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors
###end article-title 115
###begin article-title 116
###xml 38 43 <span type="species:ncbi:9606">human</span>
Analysis of the solution structure of human interleukin-4 determined by heteronuclear three-dimensional nuclear magnetic resonance techniques
###end article-title 116
###begin article-title 117
###xml 33 38 <span type="species:ncbi:9606">human</span>
The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters
###end article-title 117
###begin article-title 118
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15
###end article-title 118
###begin article-title 119
Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types
###end article-title 119
###begin article-title 120
Characterization of the interaction between interleukin-13 and interleukin-13 receptors
###end article-title 120
###begin article-title 121
Shared cytokine signaling receptors: structural insights from the gp130 system
###end article-title 121
###begin article-title 122
Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways
###end article-title 122
###begin article-title 123
A single residue of GDF-5 defines binding specificity to BMP receptor IB
###end article-title 123
###begin article-title 124
Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction
###end article-title 124
###begin article-title 125
TGF-beta signaling from a three-dimensional perspective: insight into selection of partners
###end article-title 125
###begin article-title 126
Trk receptors: mediators of neurotrophin action
###end article-title 126
###begin article-title 127
Emerging families of cytokines and receptors
###end article-title 127
###begin article-title 128
Principles of protein-protein recognition from structure to thermodynamics
###end article-title 128
###begin article-title 129
The atomic structure of protein-protein recognition sites
###end article-title 129
###begin article-title 130
Co-evolution of proteins with their interaction partners
###end article-title 130
###begin article-title 131
Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces
###end article-title 131
###begin article-title 132
A hot spot of binding energy in a hormone-receptor interface
###end article-title 132
###begin article-title 133
Comparison of a structural and a functional epitope
###end article-title 133
###begin article-title 134
The structural basis for biological signaling, regulation, and specificity in the growth hormone-prolactin system of hormones and receptors
###end article-title 134
###begin article-title 135
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 92 98 <span type="species:ncbi:10090">murine</span>
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1
###end article-title 135
###begin article-title 136
Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development
###end article-title 136
###begin article-title 137
Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130
###end article-title 137
###begin article-title 138
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain
###end article-title 138
###begin article-title 139
Dual recognition and the role of specificity-determining residues in colicin E9 DNase-immunity protein interactions
###end article-title 139
###begin article-title 140
Highly discriminating protein-protein interaction specificities in the context of a conserved binding energy hotspot
###end article-title 140
###begin article-title 141
An immune cell-selective interleukin 4 agonist
###end article-title 141
###begin article-title 142
Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells
###end article-title 142
###begin article-title 143
###xml 135 140 <span type="species:ncbi:9606">human</span>
Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease
###end article-title 143
###begin article-title 144
###xml 37 42 <span type="species:ncbi:9606">human</span>
Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy
###end article-title 144
###begin article-title 145
###xml 19 24 <span type="species:ncbi:9606">human</span>
Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding
###end article-title 145
###begin article-title 146
###xml 73 78 <span type="species:ncbi:9606">human</span>
Expression, purification, refolding, and characterization of recombinant human interleukin-13: utilization of intracellular processing
###end article-title 146
###begin article-title 147
###xml 47 52 <span type="species:ncbi:9606">human</span>
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin
###end article-title 147
###begin article-title 148
###xml 26 29 <span type="species:ncbi:10116">rat</span>
###xml 86 89 <span type="species:ncbi:10116">rat</span>
Expression of recombinant rat interleukin-13 (IL-13) and generation of a neutralizing rat IL-13 antiserum
###end article-title 148

